FSD Pharma Inc. (CVE:HUG – Free Report) – Singular Research issued their Q1 2024 earnings estimates for FSD Pharma in a report released on Tuesday, May 7th. Singular Research analyst B. Cook anticipates that the company will post earnings per share of ($0.07) for the quarter. Singular Research currently has a “Buy-Venture” rating on the stock. Singular Research also issued estimates for FSD Pharma’s Q2 2024 earnings at ($0.08) EPS, Q3 2024 earnings at ($0.08) EPS, Q4 2024 earnings at ($0.07) EPS, FY2024 earnings at ($0.30) EPS, Q1 2025 earnings at ($0.04) EPS, Q2 2025 earnings at ($0.04) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.04) EPS and FY2025 earnings at ($0.16) EPS.
FSD Pharma Stock Performance
FSD Pharma (CVE:HUG – Get Free Report) last released its quarterly earnings results on Thursday, March 28th. The company reported C($0.05) EPS for the quarter.
Featured Articles
- Five stocks we like better than FSD Pharma
- Best Aerospace Stocks Investing
- Roblox: The Bottom Just Fell Out of the Metaverse
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Airbnb Stock Plummets After Earnings, But is It a Buy?
- High Flyers: 3 Natural Gas Stocks for March 2022
- Uber’s Earnings Drop Is Investors Opportunity
Receive News & Ratings for FSD Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FSD Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
